ZURA
Zura Bio Limited
Price Chart
Latest Quote
$5.77
Current Price| Previous Close | $5.68 |
| Open | $5.68 |
| Day High | $5.95 |
| Day Low | $5.60 |
| Volume | 210,873 |
Stock Information
| Shares Outstanding | 65.02M |
| Cash Equivalents | $139.02M |
| Net Income | $-62.52M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $375.18M |
| EPS (TTM) | $-0.65 |
| Exchange | NCM |
📊 Custom Metrics & Score
Score: 19/42| Debt to Equity | 0.13 |
| Debt to Earnings | -0.37 |
| Current Ratio | 9.16 |
| Quick Ratio | 9.04 |
| Return on Equity | -35.69% |
| Avg FCF Growth | 50.37% |
| FCF Yield | -8.84% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $5.77 | 210,873 |
| 2026-01-30 | $5.68 | 641,100 |
| 2026-01-29 | $6.03 | 353,200 |
| 2026-01-28 | $5.98 | 329,800 |
| 2026-01-27 | $6.43 | 276,100 |
| 2026-01-26 | $6.38 | 464,300 |
| 2026-01-23 | $6.36 | 529,000 |
| 2026-01-22 | $6.45 | 1,612,500 |
| 2026-01-21 | $6.32 | 4,561,700 |
| 2026-01-20 | $5.01 | 762,300 |
| 2026-01-16 | $4.81 | 2,176,000 |
| 2026-01-15 | $4.69 | 1,123,600 |
| 2026-01-14 | $5.37 | 535,400 |
| 2026-01-13 | $5.16 | 296,800 |
| 2026-01-12 | $5.16 | 537,600 |
| 2026-01-09 | $5.12 | 298,300 |
| 2026-01-08 | $5.26 | 353,400 |
| 2026-01-07 | $5.28 | 745,500 |
| 2026-01-06 | $4.83 | 741,700 |
| 2026-01-05 | $4.80 | 1,274,700 |
About Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
📰 Latest News
December 2025's Top Penny Stocks With Promising Potential
Simply Wall St. • 2025-12-15T18:05:16Z
Bullish Outlook on Zura Bio Limited (ZURA) Amid Tibulizumab Phase 2 Clinical Trial Progress
Insider Monkey • 2025-11-29T06:26:01Z
Zura Bio And 2 Other Promising Penny Stocks For Your Watchlist
Simply Wall St. • 2025-10-28T12:05:05Z
Is Zura Bio’s (ZURA) Executive Severance Plan Hinting at Leadership Stability or Looming Funding Shifts?
Simply Wall St. • 2025-10-04T14:20:27Z
September 2025's Promising Penny Stocks Revealed
Simply Wall St. • 2025-09-29T18:05:32Z
Spotlight On 3 Promising Penny Stocks With Over $60M Market Cap
Simply Wall St. • 2025-08-20T12:05:13Z
3 Penny Stocks With Market Caps Over $70M Worth Watching
Simply Wall St. • 2025-07-18T12:05:08Z
We're Not Very Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Rate
Simply Wall St. • 2025-07-14T11:18:12Z
After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain
Simply Wall St. • 2025-04-24T10:34:08Z
Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock
Simply Wall St. • 2025-03-26T15:16:59Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Expenses | $55,189,000 | $62,638,000 | $27,162,000 |
| Other Income Expense | $-5,212,000 | $-111,000 | $-179,000 |
| Other Non Operating Income Expenses | $28,000 | $-2,227,000 | $-179,000 |
| Net Non Operating Interest Income Expense | $7,998,000 | $2,186,000 | $8,000 |
| Operating Expense | $55,189,000 | $62,638,000 | $27,162,000 |
| General And Administrative Expense | $30,788,000 | $18,639,000 | $3,473,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-52,403,000 | $-60,360,000 | $-25,738,000 |
| Net Interest Income | $7,998,000 | $2,186,000 | $8,000 |
| Interest Income | $7,998,000 | $2,186,000 | $8,000 |
| Normalized Income | $-47,163,000 | $-62,476,000 | $-25,738,000 |
| Net Income From Continuing And Discontinued Operation | $-52,403,000 | $-60,360,000 | $-25,738,000 |
| Total Operating Income As Reported | $-55,189,000 | $-62,638,000 | $-27,162,000 |
| Net Income Common Stockholders | $-45,386,000 | $-69,243,000 | $-32,390,000 |
| Net Income | $-52,403,000 | $-60,360,000 | $-25,738,000 |
| Net Income Including Noncontrolling Interests | $-52,403,000 | $-60,563,000 | $-27,333,000 |
| Net Income Continuous Operations | $-52,403,000 | $-60,563,000 | $-27,333,000 |
| Pretax Income | $-52,403,000 | $-60,563,000 | $-27,333,000 |
| Interest Income Non Operating | $7,998,000 | $2,186,000 | $8,000 |
| Operating Income | $-55,189,000 | $-62,638,000 | $-27,162,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Diluted EPS | $-0.60 | $-2.09 | $-12.19 |
| Basic EPS | $-0.60 | $-2.09 | $-12.19 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-49,940,000 | $-64,754,000 | $-27,162,000 |
| Total Unusual Items | $-5,240,000 | $2,116,000 | $6,223,698 |
| Total Unusual Items Excluding Goodwill | $-5,240,000 | $2,116,000 | $6,223,698 |
| Reconciled Depreciation | $9,000 | $0 | - |
| EBITDA (Bullshit earnings) | $-55,180,000 | $-62,638,000 | $-27,162,000 |
| EBIT | $-55,189,000 | $-62,638,000 | $-27,162,000 |
| Diluted Average Shares | $75,070,761 | $33,064,036 | $2,111,000 |
| Basic Average Shares | $75,070,761 | $33,064,036 | $2,111,000 |
| Diluted NI Availto Com Stockholders | $-45,386,000 | $-69,243,000 | $-32,390,000 |
| Otherunder Preferred Stock Dividend | $-7,017,000 | $8,883,000 | $6,652,000 |
| Minority Interests | $0 | $203,000 | $1,595,000 |
| Tax Provision | $0 | $0 | $0 |
| Gain On Sale Of Security | $-5,240,000 | $2,116,000 | $6,223,698 |
| Research And Development | $24,401,000 | $43,999,000 | $23,689,000 |
| Selling General And Administration | $30,788,000 | $18,639,000 | $3,473,000 |
| Other Gand A | $30,788,000 | $18,639,000 | $3,473,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-03-31 |
|---|---|---|---|---|
| Net Tangible Assets | $146,815,000 | $59,330,000 | $-32,056,000 | $-7,819,000 |
| Total Assets | $179,533,000 | $100,843,000 | $5,262,000 | $4,720,000 |
| Total Non Current Assets | $789,000 | $0 | $3,486,000 | $0 |
| Other Non Current Assets | $698,000 | - | $141,474,352 | - |
| Current Assets | $178,744,000 | $100,843,000 | $1,776,000 | $4,720,000 |
| Other Current Assets | $2,246,000 | $1,037,000 | $209,000 | - |
| Cash Cash Equivalents And Short Term Investments | $176,498,000 | $99,806,000 | $1,567,000 | $4,720,000 |
| Cash And Cash Equivalents | $176,498,000 | $99,806,000 | $1,567,000 | $4,720,000 |
| Non Current Deferred Assets | - | $0 | $3,486,000 | - |
| Cash Equivalents | - | $97,913,000 | - | - |
| Cash Financial | - | $1,893,000 | $13,785 | - |
| Prepaid Assets | - | - | $19,702 | - |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-03-31 |
|---|---|---|---|---|
| Net Debt | - | - | $6,189,000 | - |
| Total Debt | - | - | $7,756,000 | - |
| Current Debt And Capital Lease Obligation | - | - | $7,756,000 | - |
| Current Debt | - | - | $7,756,000 | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-03-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $19,514,000 | $21,292,000 | $27,318,000 | $12,539,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $990,000 | $12,500,000 | $12,500,000 |
| Derivative Product Liabilities | $0 | $990,000 | $0 | - |
| Current Liabilities | $19,514,000 | $20,302,000 | $14,818,000 | $39,000 |
| Payables And Accrued Expenses | $17,801,000 | $19,101,000 | $4,287,000 | $39,000 |
| Payables | $733,000 | $2,749,000 | $2,010,000 | - |
| Accounts Payable | $733,000 | $2,749,000 | $2,010,000 | - |
| Current Notes Payable | - | $0 | $7,756,000 | - |
| Non Current Deferred Liabilities | - | - | $4,010,000 | - |
| Other Current Liabilities | - | - | $2,634,000 | - |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-03-31 |
|---|---|---|---|---|
| Common Stock Equity | $146,815,000 | $59,330,000 | $-32,056,000 | $-7,819,000 |
| Total Equity Gross Minority Interest | $160,019,000 | $79,551,000 | $-22,056,000 | $-7,819,000 |
| Stockholders Equity | $146,815,000 | $59,330,000 | $-32,056,000 | $-7,819,000 |
| Retained Earnings | $-155,897,000 | $-103,494,000 | $-32,056,000 | $-7,819,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $12,500,000 | $12,500,000 |
| Preferred Stock Equity | - | - | - | $12,500,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-03-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $65,297,530 | $43,593,678 | $27,052,155 | $26,553,700 |
| Share Issued | $65,297,530 | $43,593,678 | $27,052,155 | $26,553,700 |
| Tangible Book Value | $146,815,000 | $59,330,000 | $-32,056,000 | $-7,819,000 |
| Invested Capital | $146,815,000 | $59,330,000 | $-24,300,000 | $-7,819,000 |
| Working Capital | $159,230,000 | $80,541,000 | $-13,042,000 | $4,681,000 |
| Total Capitalization | $146,815,000 | $59,330,000 | $-32,056,000 | $-7,819,000 |
| Minority Interest | $13,204,000 | $20,221,000 | $10,000,000 | - |
| Additional Paid In Capital | $302,705,000 | $162,820,000 | $0 | - |
| Capital Stock | $7,000 | $4,000 | $0 | $0 |
| Common Stock | $7,000 | $4,000 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $12,500,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,713,000 | $1,201,000 | $141,000 | - |
| Current Accrued Expenses | $17,068,000 | $16,352,000 | $2,277,000 | - |
| Net PPE | $91,000 | $0 | - | - |
| Dueto Related Parties Current | - | - | $78,893 | - |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Free Cash Flow | $-33,151,000 | $-23,054,000 | $-13,202,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Operating Cash Flow | $-28,076,000 | $-15,054,000 | $-1,202,000 |
| Cash Flow From Continuing Operating Activities | $-28,076,000 | $-15,054,000 | $-1,202,000 |
| Operating Gains Losses | $5,213,000 | $-741,000 | $23,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Capital Expenditure | $-5,075,000 | $-8,000,000 | $-12,000,000 |
| Investing Cash Flow | $-5,075,000 | $-8,000,000 | $-12,000,000 |
| Cash Flow From Continuing Investing Activities | $-5,075,000 | $-8,000,000 | $-12,000,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Issuance Of Capital Stock | $60,757,000 | $116,407,000 | $10,000,000 |
| Financing Cash Flow | $109,843,000 | $121,293,000 | $14,769,000 |
| Cash Flow From Continuing Financing Activities | $109,843,000 | $121,293,000 | $14,769,000 |
| Net Other Financing Charges | $-944,000 | $-1,184,000 | $-2,831,000 |
| Net Common Stock Issuance | $60,757,000 | $116,407,000 | $0 |
| Common Stock Issuance | $60,757,000 | $116,407,000 | $0 |
| Net Preferred Stock Issuance | - | $0 | $10,000,000 |
| Preferred Stock Issuance | - | $0 | $10,000,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Repayment Of Debt | $0 | $-10,000,000 | $0 |
| Interest Paid Supplemental Data | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 |
| End Cash Position | $176,498,000 | $99,806,000 | $1,567,000 |
| Beginning Cash Position | $99,806,000 | $1,567,000 | $0 |
| Changes In Cash | $76,692,000 | $98,239,000 | $1,567,000 |
| Proceeds From Stock Option Exercised | $50,030,000 | $16,070,000 | $0 |
| Net Issuance Payments Of Debt | $0 | $-10,000,000 | $7,600,000 |
| Net Short Term Debt Issuance | $0 | $-10,000,000 | $7,600,000 |
| Short Term Debt Payments | $0 | $-10,000,000 | $0 |
| Net Intangibles Purchase And Sale | $-5,000,000 | $-8,000,000 | $-12,000,000 |
| Purchase Of Intangibles | $-5,000,000 | $-8,000,000 | $-12,000,000 |
| Net PPE Purchase And Sale | $-75,000 | $0 | - |
| Purchase Of PPE | $-75,000 | $0 | - |
| Change In Working Capital | $2,307,000 | $5,116,000 | $3,541,000 |
| Change In Other Current Assets | $-698,000 | $0 | - |
| Change In Payables And Accrued Expense | $4,214,000 | $5,944,000 | $3,750,000 |
| Change In Prepaid Assets | $-1,209,000 | $-828,000 | $-209,000 |
| Stock Based Compensation | $16,798,000 | $9,655,000 | $334,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $2,244,000 | $156,000 |
| Depreciation Amortization Depletion | $9,000 | $0 | - |
| Depreciation And Amortization | $9,000 | $0 | - |
| Gain Loss On Investment Securities | $5,240,000 | $-724,000 | $-6,223,698 |
| Net Foreign Currency Exchange Gain Loss | $-27,000 | $-17,000 | $23,000 |
| Net Income From Continuing Operations | $-52,403,000 | $-60,563,000 | $-27,333,000 |
| Issuance Of Debt | - | $0 | $7,600,000 |
| Short Term Debt Issuance | - | $0 | $7,600,000 |
| Net Long Term Debt Issuance | - | $-10,000,000 | $0 |
| Long Term Debt Payments | - | $-10,000,000 | $0 |
| Other Non Cash Items | - | $29,235,000 | $22,077,000 |
| Change In Accrued Expense | - | - | $912,053 |
| Change In Payable | - | - | $288,293 |
| Change In Account Payable | - | - | $288,293 |
| Change In Receivables | - | - | $0 |